OTC:QTZM
Quantumzyme Corp.
A deeply distressed biotech startup with negative cash flow and no revenue stream, currently surviving solely through equity financing.
Key Metrics
Investment Thesis
Bull Case
Investors might consider QTZM as a high-risk speculative play on a potential breakthrough biotech product that could unlock massive value upon commercialization. The company's low current asset count suggests a lean operational footprint, and successful financing rounds indicate some level of investor belief in the underlying technology.
Bear Case
The stock is fundamentally unsound with total liabilities exceeding assets by nearly $441k and no path to profitability visible from the financial data. The negative net income trend and massive interest expense suggest an imminent risk of delisting or bankruptcy without a miraculous turnaround.
About Quantumzyme Corp.
Quantumzyme Corp. (QTZM) is an OTC-traded biotechnology entity focused on developing novel enzymatic solutions, currently operating with minimal revenue generation. The company faces significant liquidity challenges as it relies on financing activities to cover substantial operational losses and interest expenses. With a current assets base of only $584 against liabilities exceeding $441k, the firm is in a critical financial position requiring immediate capital injection.
Analysis
Management Discussion
The company reported a net loss of -$199,269 driven by operating expenses of $180,537 and significant interest expense of $21,232. While cash flow from financing provided $125,765 in capital, the entity burned through most of this to cover operations, resulting in a retained earnings deficit of -$5.6M and negative working capital.
Industry Overview
The biotechnology industry is capital-intensive and competitive, requiring significant R&D investment and regulatory approval before products reach market. Companies in this space typically face years of losses before generating revenue, making early-stage firms highly volatile assets dependent on continuous funding.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2025 |
|---|---|
| Revenue | $0 |
| Cost of Revenue | $0 |
| Gross Profit | $0 |
| Operating Expenses | $180.5K |
| Operating Income | $-180.5K |
| G&A | $18.1K |
| Other OpEx | $162.4K |
| Non-Operating Income | $-18.7K |
| Interest Expense | $21.2K |
| Pre-Tax Income | $-199.3K |
| Income Tax | $0 |
| Continuing Ops | $-199.3K |
| Discontinued Ops | $0 |
| Net Income | $-199.3K |
| Minority Interest | $0 |
| Net to Common | $-199.3K |
| Metric | 2025 |
|---|---|
| Current Assets | $584 |
| Long-Term Assets | $0 |
| Total Assets | $584 |
| Current Liabilities | $441.3K |
| Long-Term Liabilities | $0 |
| Total Liabilities | $441.3K |
| Shareholders' Equity | $-440.7K |
| Paid-In Capital | $5.2M |
| Retained Earnings | $-5.6M |
| Total L&E | $584 |
| Metric | 2025 |
|---|---|
| Net Income (CFO) | $-199.3K |
| Non-Cash Adjustments | $18.6K |
| Working Capital Changes | $55.4K |
| Cash from Operations | $-125.2K |
| Cash from Investing | $0 |
| Cash from Financing | $125.8K |
| FX Effect | $0 |
| Net Change in Cash | $584 |
| Beginning Cash | $0 |
| Ending Cash | $584 |
Frequently Asked Questions
How does Quantumzyme Corp. make money?
Enzymatic Product Development (no current sales), Research & Development (operating loss driver), and Capital Raising Activities (primary source of cash inflow).
What are the main risks for QTZM?
Severe liquidity crisis with current liabilities vastly exceeding assets, unsustainable net losses of nearly $200k annually, complete absence of revenue or gross profit, and high risk of insolvency without further financing.
What is QTZM's competitive advantage?
Proprietary enzymatic intellectual property pending validation, potential high-margin future revenue streams if product commercialization succeeds, and low burn rate relative to typical biotech peers due to current lack of operations.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.